STAR Pharmaceutical Limited reported un-audited group earnings results for the first quarter ended March 31, 2018. For the quarter, the group reported revenue of RMB 67.5 million compared to RMB 19.9 million, profit from operations of RMB 9.4 million compared to RMB 5.0 million, profit before income tax of RMB 7.4 million compared to RMB 4.6 million, profit attributable to equity holders of the company of RMB 6.9 million or 14.78 RMB cents per diluted share compared to RMB 3.9 million or 8.44 RMB cents per diluted share, net cash generated from operating activities of RMB 5.7 million compared to RMB 9.3 million and purchase of property, plant and equipment of RMB 0.043 million compared to RMB 2.8 million for the same period a year ago. Payment for product development in progress was RMB 1.9 million. Group revenue increased 239% from in first quarter of 2017 due to higher revenue of antibiotics, Cardiovasular drugs and Cerebovascular drugs and other specialized drugs. Net cash inflow from operating activities was increased mainly due to the operating profit from group's usual operating business for first quarter of 2018.